Fusion Antibodies PLC (LSE:FAB) — Market Cap & Net Worth
Market Cap & Net Worth: Fusion Antibodies PLC (FAB)
Fusion Antibodies PLC (LSE:FAB) has a market capitalization of $145.20K (GBX1.19 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31264 globally and #1056 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fusion Antibodies PLC's stock price GBX10.50 by its total outstanding shares 113656253 (113.66 Million). See Fusion Antibodies PLC capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Fusion Antibodies PLC Market Cap History: 2017 to 2026
Fusion Antibodies PLC's market capitalization history from 2017 to 2026. Data shows change from $2.95 Million to $145.20K (-24.83% CAGR).
Index Memberships
Fusion Antibodies PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$927.28 Million | 0.02% | #315 of 722 |
Weight: Fusion Antibodies PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fusion Antibodies PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fusion Antibodies PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Fusion Antibodies PLC's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.95 Million | $1.91 Million | $119.95K | 1.54x | 24.56x |
| 2018 | $753.66K | $2.69 Million | -$699.94K | 0.28x | N/A |
| 2019 | $1.09 Million | $2.18 Million | -$1.26 Million | 0.50x | N/A |
| 2020 | $1.71 Million | $3.90 Million | -$697.00K | 0.44x | N/A |
| 2021 | $1.56 Million | $4.17 Million | -$2.90 Million | 0.37x | N/A |
| 2022 | $622.29K | $4.80 Million | -$1.20 Million | 0.13x | N/A |
| 2023 | $58.77K | $2.90 Million | -$2.60 Million | 0.02x | N/A |
| 2024 | $97.49K | $1.14 Million | -$2.23 Million | 0.09x | N/A |
| 2025 | $193.60K | $1.97 Million | -$1.71 Million | 0.10x | N/A |
Competitor Companies of FAB by Market Capitalization
Companies near Fusion Antibodies PLC in the global market cap rankings as of August 7, 2026.
Key companies related to Fusion Antibodies PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Fusion Antibodies PLC Historical Marketcap From 2017 to 2026
Between 2017 and today, Fusion Antibodies PLC's market cap moved from $2.95 Million to $ 145.20K, with a yearly change of -24.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX145.20K | -25.00% |
| 2025 | GBX193.60K | +98.58% |
| 2024 | GBX97.49K | +65.88% |
| 2023 | GBX58.77K | -90.56% |
| 2022 | GBX622.29K | -60.00% |
| 2021 | GBX1.56 Million | -9.27% |
| 2020 | GBX1.71 Million | +57.96% |
| 2019 | GBX1.09 Million | +44.04% |
| 2018 | GBX753.66K | -74.41% |
| 2017 | GBX2.95 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Fusion Antibodies PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $145.20K USD |
| MoneyControl | $145.20K USD |
| MarketWatch | $145.20K USD |
| marketcap.company | $145.20K USD |
| Reuters | $145.20K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more